Study S003373

Efficacy and Safety of HDM1005 Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial

ClinicalTrials.gov record

Registration

Registration: NCT07279194
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 825
Start: 2025-10-14
Primary completion: 2026-09-20
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Obesity & Overweight
Interventions: DRUG:HDM1005 1; DRUG:HDM1005 2; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

primary outcome [week 40]
Co-primary outcome [week 40]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.